Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma

Amy Skorupa; Matthew Beldner; Andrew Kraft; Alberto J. Montero

doi:10.4161/cbt.6.7.4338

Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma

Amy Skorupa, Matthew Beldner, Andrew Kraft, Alberto J. Montero

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Rhabdomyolysis is a clinical syndrome in which skeletal muscle damage and necrosis leads to the release of intracellular muscle contents, which can ultimately lead to electrolyte disturbances, renal failure and even death. Chemotherapy is an extremely rare cause of rhabdomyolysis. Herein, we describe a fatal case of rhabdomyolysis in a patient with metastatic sarcoma after receiving the chemotherapeutic agent Ecteinascidin-743 (ET-743, trabectedin) as palliative chemotherapy treatment.

Original language	English (US)
Pages (from-to)	1015-1017
Number of pages	3
Journal	Cancer Biology and Therapy
Volume	6
Issue number	7
DOIs	https://doi.org/10.4161/cbt.6.7.4338
State	Published - Jul 2007

Keywords

Ecteinascidin-743 (Yondelis)
Rhabdomyolysis
Sarcoma

ASJC Scopus subject areas

Molecular Medicine
Oncology
Pharmacology
Cancer Research

Access to Document

10.4161/cbt.6.7.4338

Cite this

@article{48a4d7ddd4c24ff4b48a9382b5b8a6e2,

title = "Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma",

abstract = "Rhabdomyolysis is a clinical syndrome in which skeletal muscle damage and necrosis leads to the release of intracellular muscle contents, which can ultimately lead to electrolyte disturbances, renal failure and even death. Chemotherapy is an extremely rare cause of rhabdomyolysis. Herein, we describe a fatal case of rhabdomyolysis in a patient with metastatic sarcoma after receiving the chemotherapeutic agent Ecteinascidin-743 (ET-743, trabectedin) as palliative chemotherapy treatment.",

keywords = "Ecteinascidin-743 (Yondelis), Rhabdomyolysis, Sarcoma",

author = "Amy Skorupa and Matthew Beldner and Andrew Kraft and Montero, {Alberto J.}",

year = "2007",

month = jul,

doi = "10.4161/cbt.6.7.4338",

language = "English (US)",

volume = "6",

pages = "1015--1017",

journal = "Cancer Biology and Therapy",

issn = "1538-4047",

publisher = "Landes Bioscience",

number = "7",

}

TY - JOUR

T1 - Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma

AU - Skorupa, Amy

AU - Beldner, Matthew

AU - Kraft, Andrew

AU - Montero, Alberto J.

PY - 2007/7

Y1 - 2007/7

N2 - Rhabdomyolysis is a clinical syndrome in which skeletal muscle damage and necrosis leads to the release of intracellular muscle contents, which can ultimately lead to electrolyte disturbances, renal failure and even death. Chemotherapy is an extremely rare cause of rhabdomyolysis. Herein, we describe a fatal case of rhabdomyolysis in a patient with metastatic sarcoma after receiving the chemotherapeutic agent Ecteinascidin-743 (ET-743, trabectedin) as palliative chemotherapy treatment.

AB - Rhabdomyolysis is a clinical syndrome in which skeletal muscle damage and necrosis leads to the release of intracellular muscle contents, which can ultimately lead to electrolyte disturbances, renal failure and even death. Chemotherapy is an extremely rare cause of rhabdomyolysis. Herein, we describe a fatal case of rhabdomyolysis in a patient with metastatic sarcoma after receiving the chemotherapeutic agent Ecteinascidin-743 (ET-743, trabectedin) as palliative chemotherapy treatment.

KW - Ecteinascidin-743 (Yondelis)

KW - Rhabdomyolysis

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=42449133375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449133375&partnerID=8YFLogxK

U2 - 10.4161/cbt.6.7.4338

DO - 10.4161/cbt.6.7.4338

M3 - Article

C2 - 17611408

AN - SCOPUS:42449133375

SN - 1538-4047

VL - 6

SP - 1015

EP - 1017

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

IS - 7

ER -

Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this